卡培他滨治疗对氟尿嘧啶耐药的晚期转移性大肠癌的疗效观察

Curative effect observation on Capecitabine treatment of fluorouracil-resistant metastatic colorectal cancer with advanced cancer

目的探讨62例对5-氟尿嘧啶(5-FU)耐药的晚期转移性大肠癌患者接受卡培他滨(希罗达)治疗的疗效。方法62例晚期转移性大肠癌患者既往应用含5-FU方案多周期化疗,在行希罗达治疗前至少有4周未行化疗。每日口服卡培他滨2510mg/m2(分2次口服),连用14d,停药7d,每21d为1个周期,每周期均进行癌胚抗原(CEA)测定和影像学检查。结果62例患者总有效率为18%,总体至病情进展的平均时间为21周,平均生存期为10.4个月。结论已经对5-氟尿嘧啶(5-FU)产生耐药性的晚期大肠癌患者,经卡培他滨(希罗达)治疗,仍然有较高的有效率,而且毒性反应可以耐受,不影响继续治疗。

Objective To inquire into the curative effect of the capecitabine to 62 patients with carcinoma of large intestine that advanced and transfevent and drug--resistant to Fluorouracil（5- FU）. Methods All the 62 patients with carcinoma of large intestine that advanced and transfevent had chemo-therapies hy project with 5-FU multiplicity cycles, no any treatment at least 4 weeks before use capecitabine. Capecitabine for oral use every day, 2510 mg/m^2 bid, continuity 14 days, withdrawal 7 days. One cycle was every 21 days. Each cycle follows up examination CEA and iconography. Results 62 patients grand total effective rate was 18%, average time of population to exacerbation was 21 weeks. Average survival time was 10.4 months. Conclusions Through used capecitabine to cure the patient with carcinoma of large intestine that is advanced and transfevent and drug-resistant to 5-FU , can still get major effective rate, and all toxic effect can be tolerated, and all patients can be cured completely.